martes, 5 de julio de 2016

National Guideline Clearinghouse | Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

National Guideline Clearinghouse | Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

National Guideline Clearinghouse (NGC)

National Institute for Health and Care Excellence (NICE)


Guideline Title
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia.
Bibliographic Source(s)
National Institute for Health and Care Excellence (NICE). Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Feb 24. 22 p. (Technology appraisal guidance; no. 385). 
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Nov. 30 p. (Technology appraisal guidance; no. 132).
This guideline meets NGC's 2013 (revised) inclusion criteria.

No hay comentarios:

Publicar un comentario